{"entity":{"id":"nct07498478","kind":"trial","name":"Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment","aka":[],"tldr":"A phase 2 trial of Fulvestrant and Tinengotinib in HR-positive / HER2-negative breast cancer, run by TransThera Sciences (Nanjing), Inc., now recruiting.","summary":"Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment is a phase 2 interventional study registered as NCT07498478 by TransThera Sciences (Nanjing), Inc., with 94 participants planned, started 2026-03-17 and due to reach its primary completion in 2027-06-30. Interventions recorded: Tinengotinib at the optimal dose combined with Fulvestrant, Tinengotinib and tinengotinib combined with fulvestrant.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07498478","url":"https://clinicaltrials.gov/study/NCT07498478"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["fulvestrant","tinengotinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07498478","phase":"2","setting":"A Phase II, Open-Label, Multicenter Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of TT-00420 (Tinengotinib) Tablets Combined With Fulvestrant Injection in Patients With Hormone Receptor-Positive (HR+) and Human Epidermal Growth Factor Receptor 2 (HER-2) Negative or Low-Expressing Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment","sponsor":"TransThera Sciences (Nanjing), Inc.","enrolled":94,"outcomes":[]},"route":"/trials/nct07498478/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"drug":[{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/"},{"id":"tinengotinib","kind":"drug","name":"Tinengotinib","route":"/drugs/tinengotinib/"}]}}